



4160-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2010-D-0249]

Guidance for Industry on Lupus Nephritis Caused By Systemic Lupus Erythematosus--
Developing Medical Products for Treatment; Withdrawal of Guidance

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; withdrawal.

SUMMARY: The Food and Drug Administration (FDA) is announcing the withdrawal of a guidance published in the Federal Register of June 22, 2010.

DATES: [INSERT DATE OF PUBLICATION IN THE FEDERAL REGISTER].

FOR FURTHER INFORMATION CONTACT:

Leila P. Hann,
Center for Drug Evaluation and Research,
Food and Drug Administration,
10903 New Hampshire Ave.,
Bldg. 22, rm. 3143,
Silver Spring, MD 20993-0002,
301-796-3367;
or
Philip Desjardins,
Center for Devices and Radiological Health,
Food and Drug Administration,

10903 New Hampshire Ave.,
Bldg. 66, rm. 5437,
Silver Spring, MD 20993-0002,
301-796-5678;

or

Stephen Ripley,
Center for Biologics Evaluation and Research (HFM-17),
Food and Drug Administration,
1401 Rockville Pike, suite 200N,
Rockville, MD 20852-1448,
301-827-6210.

SUPPLEMENTARY INFORMATION: In a notice published in the Federal Register of June 22, 2010 (75 FR 35492), FDA announced the availability of a guidance entitled “Lupus Nephritis Caused By Systemic Lupus Erythematosus--Developing Medical Products for Treatment.” This guidance is being withdrawn because it does not reflect FDA’s current thinking on the development of medical products for the treatment of lupus nephritis.

Dated: June 22, 2012.

Leslie Kux,
Assistant Commissioner for Policy.

[FR Doc. 2012-15716 Filed 06/26/2012 at 8:45 am; Publication Date: 06/27/2012]